The FDA approved the oral combination of decitabine and cedazuridine (Inqovi, Astex) for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
This combination product is an important advance in treatment options for patients with MDS, who previously needed to visit a health care facility to receive IV therapy, the agency said.
The combination is indicated for MDS patients who:
- were previously treated and untreated, de novo and secondary MDS